Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00206024 |
This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.
Condition | Intervention | Phase |
---|---|---|
Heartburn |
Drug: Esomeprazole magnesium |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 4-Week Study to Investigate the Relationship Between Resolution of Acid-Associated Heartburn Symptoms and Dose of Esomeprazole Magnesium |
Estimated Enrollment: | 330 |
Study Start Date: | November 2004 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Nexium Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D9612L00064 |
Study First Received: | September 12, 2005 |
Last Updated: | June 21, 2006 |
ClinicalTrials.gov Identifier: | NCT00206024 |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Pyrosis Signs and Symptoms, Digestive Heartburn Omeprazole |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |